Simultaneous Drug Targeting of the Promoter MYC G-Quadruplex and BCL2 i-Motif in Diffuse Large B-Cell Lymphoma Delays Tumor Growth

Samantha Kendrick, Andrea Muranyi, Vijay Gokhale, Laurence H. Hurley, Lisa Rimsza

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Secondary DNA structures are uniquely poised as therapeutic targets due to their molecular switch function in turning gene expression on or off and scaffold-like properties for protein and small molecule interaction. Strategies to alter gene transcription through these structures thus far involve targeting single DNA conformations. Here we investigate the feasibility of simultaneously targeting different secondary DNA structures to modulate two key oncogenes, cellular-myelocytomatosis (MYC) and B-cell lymphoma gene-2 (BCL2), in diffuse large B-cell lymphoma (DLBCL). Cotreatment with previously identified ellipticine and pregnanol derivatives that recognize the MYC G-quadruplex and BCL2 i-motif promoter DNA structures lowered mRNA levels and subsequently enhanced sensitivity to a standard chemotherapy drug, cyclophosphamide, in DLBCL cell lines. In vivo repression of MYC and BCL2 in combination with cyclophosphamide also significantly slowed tumor growth in DLBCL xenograft mice. Our findings demonstrate concurrent targeting of different DNA secondary structures offers an effective, precise, medicine-based approach to directly impede transcription and overcome aberrant pathways in aggressive malignancies.

Original languageEnglish (US)
Pages (from-to)6587-6597
Number of pages11
JournalJournal of Medicinal Chemistry
Volume60
Issue number15
DOIs
StatePublished - Aug 10 2017

Fingerprint

G-Quadruplexes
Lymphoma, Large B-Cell, Diffuse
B-Cell Lymphoma
Drug Delivery Systems
ellipticine
Growth
Cyclophosphamide
Genes
DNA
Neoplasms
Nucleic Acid Conformation
Nucleotide Motifs
Oncogenes
Heterografts
Medicine
Gene Expression
Drug Therapy
Cell Line
Messenger RNA
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Simultaneous Drug Targeting of the Promoter MYC G-Quadruplex and BCL2 i-Motif in Diffuse Large B-Cell Lymphoma Delays Tumor Growth. / Kendrick, Samantha; Muranyi, Andrea; Gokhale, Vijay; Hurley, Laurence H.; Rimsza, Lisa.

In: Journal of Medicinal Chemistry, Vol. 60, No. 15, 10.08.2017, p. 6587-6597.

Research output: Contribution to journalArticle

Kendrick, Samantha ; Muranyi, Andrea ; Gokhale, Vijay ; Hurley, Laurence H. ; Rimsza, Lisa. / Simultaneous Drug Targeting of the Promoter MYC G-Quadruplex and BCL2 i-Motif in Diffuse Large B-Cell Lymphoma Delays Tumor Growth. In: Journal of Medicinal Chemistry. 2017 ; Vol. 60, No. 15. pp. 6587-6597.
@article{06eed968c4844a4198a4e52566f968dc,
title = "Simultaneous Drug Targeting of the Promoter MYC G-Quadruplex and BCL2 i-Motif in Diffuse Large B-Cell Lymphoma Delays Tumor Growth",
abstract = "Secondary DNA structures are uniquely poised as therapeutic targets due to their molecular switch function in turning gene expression on or off and scaffold-like properties for protein and small molecule interaction. Strategies to alter gene transcription through these structures thus far involve targeting single DNA conformations. Here we investigate the feasibility of simultaneously targeting different secondary DNA structures to modulate two key oncogenes, cellular-myelocytomatosis (MYC) and B-cell lymphoma gene-2 (BCL2), in diffuse large B-cell lymphoma (DLBCL). Cotreatment with previously identified ellipticine and pregnanol derivatives that recognize the MYC G-quadruplex and BCL2 i-motif promoter DNA structures lowered mRNA levels and subsequently enhanced sensitivity to a standard chemotherapy drug, cyclophosphamide, in DLBCL cell lines. In vivo repression of MYC and BCL2 in combination with cyclophosphamide also significantly slowed tumor growth in DLBCL xenograft mice. Our findings demonstrate concurrent targeting of different DNA secondary structures offers an effective, precise, medicine-based approach to directly impede transcription and overcome aberrant pathways in aggressive malignancies.",
author = "Samantha Kendrick and Andrea Muranyi and Vijay Gokhale and Hurley, {Laurence H.} and Lisa Rimsza",
year = "2017",
month = "8",
day = "10",
doi = "10.1021/acs.jmedchem.7b00298",
language = "English (US)",
volume = "60",
pages = "6587--6597",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "15",

}

TY - JOUR

T1 - Simultaneous Drug Targeting of the Promoter MYC G-Quadruplex and BCL2 i-Motif in Diffuse Large B-Cell Lymphoma Delays Tumor Growth

AU - Kendrick, Samantha

AU - Muranyi, Andrea

AU - Gokhale, Vijay

AU - Hurley, Laurence H.

AU - Rimsza, Lisa

PY - 2017/8/10

Y1 - 2017/8/10

N2 - Secondary DNA structures are uniquely poised as therapeutic targets due to their molecular switch function in turning gene expression on or off and scaffold-like properties for protein and small molecule interaction. Strategies to alter gene transcription through these structures thus far involve targeting single DNA conformations. Here we investigate the feasibility of simultaneously targeting different secondary DNA structures to modulate two key oncogenes, cellular-myelocytomatosis (MYC) and B-cell lymphoma gene-2 (BCL2), in diffuse large B-cell lymphoma (DLBCL). Cotreatment with previously identified ellipticine and pregnanol derivatives that recognize the MYC G-quadruplex and BCL2 i-motif promoter DNA structures lowered mRNA levels and subsequently enhanced sensitivity to a standard chemotherapy drug, cyclophosphamide, in DLBCL cell lines. In vivo repression of MYC and BCL2 in combination with cyclophosphamide also significantly slowed tumor growth in DLBCL xenograft mice. Our findings demonstrate concurrent targeting of different DNA secondary structures offers an effective, precise, medicine-based approach to directly impede transcription and overcome aberrant pathways in aggressive malignancies.

AB - Secondary DNA structures are uniquely poised as therapeutic targets due to their molecular switch function in turning gene expression on or off and scaffold-like properties for protein and small molecule interaction. Strategies to alter gene transcription through these structures thus far involve targeting single DNA conformations. Here we investigate the feasibility of simultaneously targeting different secondary DNA structures to modulate two key oncogenes, cellular-myelocytomatosis (MYC) and B-cell lymphoma gene-2 (BCL2), in diffuse large B-cell lymphoma (DLBCL). Cotreatment with previously identified ellipticine and pregnanol derivatives that recognize the MYC G-quadruplex and BCL2 i-motif promoter DNA structures lowered mRNA levels and subsequently enhanced sensitivity to a standard chemotherapy drug, cyclophosphamide, in DLBCL cell lines. In vivo repression of MYC and BCL2 in combination with cyclophosphamide also significantly slowed tumor growth in DLBCL xenograft mice. Our findings demonstrate concurrent targeting of different DNA secondary structures offers an effective, precise, medicine-based approach to directly impede transcription and overcome aberrant pathways in aggressive malignancies.

UR - http://www.scopus.com/inward/record.url?scp=85027268102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027268102&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.7b00298

DO - 10.1021/acs.jmedchem.7b00298

M3 - Article

VL - 60

SP - 6587

EP - 6597

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 15

ER -